# Agenus

Source: https://onco.cc/companies/agenus/  
OnCo record `agenus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Agenus is a Massachusetts immuno-oncology company developing botensilimab, an Fc-enhanced anti-CTLA-4 antibody, with its anti-PD-1 balstilimab, notably in microsatellite-stable colorectal cancer where checkpoint inhibitors have not worked.

## Summary

Agenus, based in Lexington, Massachusetts and listed on Nasdaq, develops checkpoint antibodies and cancer vaccines. Its lead combination is botensilimab, a next-generation anti-CTLA-4 antibody with an engineered Fc region, given with balstilimab, an anti-PD-1 antibody, which has shown responses in microsatellite-stable colorectal cancer without liver metastases and other cold tumours; the company has sought accelerated approval and runs registrational trials. In January 2026 it completed the sale of its manufacturing operations to Zydus for USD 75 million before closing deductions, which also brought into effect a licence giving Zydus the combination in India and Sri Lanka. In July 2026 it raised about USD 85 million upfront in a private placement to fund ROBBIN, a planned registrational phase 3 trial of botensilimab and balstilimab given before surgery in microsatellite-stable colon cancer, and said it would stop funding the BATTMAN phase 3 trial in late-line metastatic disease. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Agenus Inc.; Agenus Inc
- Tags: ctgov-sponsor
- HQ: Lexington, MA
- Type: biotech
- Website: https://agenusbio.com

## Notes

- Freshened 29 October 2026 from SEC EDGAR: Form 8-K of 16 January 2026 (Zydus asset sale closed 15 January 2026) and the press release filed with the Form 8-K of 13 July 2026 (private placement of about USD 85 million upfront and up to USD 255 million more on warrant exercise; BATTMAN funding stopped). Agenus was not acquired.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Agenus
- Official website: https://agenusbio.com
- SEC Form 8-K: Zydus asset sale completed (15 January 2026): https://www.sec.gov/Archives/edgar/data/1098972/000119312526014678/agen-20260115.htm
- Agenus press release on the ROBBIN financing (13 July 2026, filed with the SEC): https://www.sec.gov/Archives/edgar/data/1098972/000119312526301414/d111026dex991.htm
- ClinicalTrials.gov: trials led by Agenus: https://clinicaltrials.gov/search?lead=Agenus
- Wikipedia: https://en.wikipedia.org/wiki/Agenus

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Balstilimab](https://onco.cc/drugs/balstilimab/), [Botensilimab](https://onco.cc/drugs/botensilimab/), [Ivermectin](https://onco.cc/drugs/ivermectin/), [Zalifrelimab](https://onco.cc/drugs/zalifrelimab/)
- companies: [Zydus Lifesciences](https://onco.cc/companies/zydus/)
- trials: [A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy](https://onco.cc/trials/nct07227636/), [A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma](https://onco.cc/trials/nct06843434/), [A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer](https://onco.cc/trials/nct05608044/), [A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab](https://onco.cc/trials/nct06782555/), [Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)](https://onco.cc/trials/nct05318469/), [Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct06300463/), [RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer](https://onco.cc/trials/nct07735624/), [Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers](https://onco.cc/trials/nct05205330/)
- key papers: [Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial](https://onco.cc/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/)
- ideas: [Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed](https://onco.cc/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/)

---
JSON: https://onco.cc/api/v1/entities/agenus.json